



What is it famous for? Two words:
DNA sequencing. Although initially
focused on sequencing cDNAs, The
Institute for Genomic Research
(TIGR) is perhaps best known for
completing the first genomic
sequence of a living organism. That
sequence, of the bacterium
Haemophilus influenzae, was published
in 1995 and was soon followed by
that of Mycoplasma genitalium. Since
then, about a dozen microorganism
genomes have been sequenced, half
of them by TIGR. Perhaps the most
famous of these is that of the Archae
bacteria Methanococcus jannaschii,
sequenced two years ago, which
TIGR founder and president J. Craig
Venter hailed as the first genome from
the third domain of life.
How was TIGR started? During his
career at the National Institutes of
Health (NIH), Venter became
increasingly frustrated with the time
and money lavished on isolating
individual genes. So he developed a
way of sequencing fragments of
randomly selected cDNA clones —
so-called ‘expressed sequence tags’
(ESTs) — which would represent
active genes. Despite harsh criticism
from some prominent academics, the
potential of this approach soon
outstripped his crowded, dilapidated
lab space at NIH (and NIH’s
willingness to bankroll the work).
So, in 1992, Venter founded TIGR.
Where did the funding come from?
TIGR was set up as a non-profit
research institute, with the backing
of an $85 million loan from a
venture capital company by way of
Human Genome Sciences (HGS), a
young biotechnology company
headed by ex-Harvard AIDS
researcher William Haseltine.
Did the TIGR–HGS partnership work?
In many respects it was a perfect
match — at least to begin with.
TIGR received generous start-up
funds to develop a formidable
sequencing and bioinformatics
operation. The Institute is based a
few miles from the NIH in
Rockville, Maryland, and employs
about 170 staff and almost as many
DNA sequencing machines. HGS,
meanwhile, received exclusive
licensing rights to a few of the most
therapeutically promising clones
identified by TIGR, as well as help
in optimizing cDNA sequencing
technology. The company has
applied for numerous patents on the
basis of its cDNA sequencing data.
Have Venter and Haseltine made
headlines? You bet they have. The
pair appeared on the cover of Business
Week as “The Gene Kings”, but most
publications considered the duo “the
odd couple” for their contrasting
styles. Although Venter accrued
considerable wealth from his stock in
HGS, part of which he lavished on
honing his sailing skills — he won a
trans-Atlantic race in 1997 — he
insisted he was not in it for the
money. The debonair Haseltine, by
contrast, relishes his celebrity status.
What has come out of the partnership?
The pinnacle of the TIGR–HGS
collaboration came in 1995, when they
published the ‘Genome Directory’ in
Nature — sequence and expression
information on 350,000 human ESTs
(83 million nucleotides),
representing the majority
of human genes. But as
TIGR came to focus more
on microorganisms and
HGS on therapeutics,
there were fewer reasons
to stay together. Last year,
TIGR and HGS arranged
an amicable divorce, with
Venter turning down the
final $38 million payment
from HGS in return for
the freedom to pursue
other options.
What will TIGR do now? Last month,
Venter shocked the biomedical
community by announcing an
audacious plan, to form a new
company with Perkin-Elmer
Corporation and sequence almost the
entire human genome in three years.
How is Venter proposing to achieve this?
Two years ago, Venter and colleagues
proposed that shotgun cloning, which
has been so successful for sequencing
the genomes of microorganisms, could
be scaled-up to the human genome.
Combine that strategy with an army
of 300 of Perkin-Elmer’s next-
generation automated DNA
sequencing machines, churning out
millions of bases around the clock,
and you have the foundation of a new
company (which has yet to be
named). Venter will take over the new
company, leaving TIGR in the
capable hands of its research director
— Venter’s wife — Claire Fraser.
Will the new sequencing enterprise
work? Scientists at the NIH have
reacted cautiously, saying it will take
18 months to judge the likely success
of Venter’s new company. In the
meantime, it remains all systems go
on the federal genome project.
Venter says sequence data will be
released into public databases every
three months, with his company
seeking to patent, at most, a few
hundred genes. The $200 million
cost of the sequencing enterprise will
be recouped from subscribers to a
private sequence database.
R440 Current Biology, Vol 8 No 13
